Jason Kelly, chief executive of Ginkgo Bioworks, spent a surprising amount of time on an earnings call with analysts last ...
Ginkgo Bioworks (NYSE:DNA) used its fourth-quarter earnings call to outline a sharpened strategic focus for 2026 centered on ...
Why Ginkgo Bioworks is back on investors’ radar Ginkgo Bioworks Holdings (DNA) has drawn fresh attention after reporting full year 2025 results that paired lower sales with a smaller net loss, ...
Ginkgo Bioworks Holdings, Inc. ((DNA)) has held its Q4 earnings call. Read on for the main highlights of the call. Ginkgo Bioworks’ latest earnings call struck a cautiously optimistic tone as ...
Shares of Ginkgo Bioworks fell after the company reported lower fourth-quarter revenue and said it would sell its biosecurity business in exchange for a minority equity position in the business. The ...
Ginkgo Bioworks' new Ginkgo Cloud Lab interface will let researchers transition their benchwork to Ginkgo’s autonomous lab ...
Embedded AI safety layer blocks LLMs from generating novel chemical threat agents using Lunai’s proprietary biology and ...
Ginkgo's future may be promising, but whether the company can realize its potential is debatable. Special purpose acquisition companies (SPACs) were popular in 2021 while investors were buying up meme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results